Kazuto Matsuura

Prof. Dr. Kazuto Matsuura


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Cancer Letters
Verified
Journal Article
Closed access
SMShinkichi Morita
Shinkichi Morita
MMMai Mochizuki
Mai Mochizuki
KWKouichi Wada
Kouichi Wada
RSRie Shibuya
Rie Shibuya
MNMao Nakamura
Mao Nakamura
KTKeiichi Tamai
Keiichi Tamai

25 July 2012 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SKSatoshi Kano
Satoshi Kano
AHAkihiro Homma
Akihiro Homma
RHRyuichi Hayashi
Ryuichi Hayashi
KKKazuyoshi Kawabata
Kazuyoshi Kawabata
KYKunitoshi Yoshino
Kunitoshi Yoshino
MFMasato Fujii
Masato Fujii

26 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TSTakeshi Shinozaki
Takeshi Shinozaki
KMKazuto Matsuura
Kazuto Matsuura
WOWataru Okano
Wataru Okano
TTToshifumi Tomioka
Toshifumi Tomioka
YNYukio Nishiya
Yukio Nishiya
Ryuichi HayashiRyuichi Hayashi
Ryuichi Hayashi
Photoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunotherapy was indicated by a retrospective chart review. Patients aged ≥20 years diagnosed with advanced or recurrent head and neck cancer who started receiving systemic therapy at the National Cancer Center Hospital East from January 2016 through December 2020 were retrospectively analyzed. Before and after first-line systemic therapy, patients were classified into 3 groups according to eligibility for photoimmunotherapy: eligible, potentially eligible, and ineligible. In total, of 246 patients evaluated—194 after exclusions were analyzed—108 were deemed ineligible for treatment. Of the remaining 86 patients, 8 were considered potentially eligible and 9 eligible. Of the nine eligible patients, four became ineligible after receiving first-line systemic therapy due to disease progression. Our results suggest that the indication of photoimmunotherapy should be considered before, during, and after systemic therapy for unresectable locally advanced or recurrent head and neck cancer.

8 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
THTakashi Hirai
Takashi Hirai
YNYujiro Naito
Yujiro Naito
SKShohei Koyama
Shohei Koyama
YNYoshimitsu Nakanishi
Yoshimitsu Nakanishi
KMKentaro Masuhiro
Kentaro Masuhiro
AKAtsushi Kumanogoh
Atsushi Kumanogoh
Immune checkpoint inhibitors (ICIs) are indicated for a diverse range of cancer types, and characterizing the tumor immune microenvironment is critical for optimizing therapeutic strategies, including ICIs. T cell infiltration and activation status in the tumor microenvironment greatly affects the efficacy of ICIs. Here, we show that semaphorin 6D (Sema6D) forward signaling, which is reportedly involved in coordinating the orientation of cell development and migration as a guidance factor, impaired the infiltration and activation of tumor-specific CD8 + T cells in murine oral tumors. Sema6D expressed by nonhematopoietic cells was responsible for this phenotype. Plexin-A4, a receptor for Sema6D, inhibited T cell infiltration and partially suppressed CD8 + T cell activation and proliferation induced by Sema6D stimulation. Moreover, mouse oral tumors, which are resistant to PD-1–blocking treatment in wild-type mice, showed a response to the treatment in Sema6d -KO mice. Finally, analyses of public data sets of human head and neck squamous cell carcinoma, pan-cancer cohorts, and a retrospective cohort study showed that SEMA6D was mainly expressed by nonhematopoietic cells such as cancer cells, and SEMA6D expression was significantly negatively correlated with CD8A , PDCD1 , IFNG , and GZMB expression. Thus, targeting Sema6D forward signaling is a promising option for increasing ICI efficacy.

1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SSSatoshi Saijoh
Satoshi Saijoh
MNMao Nakamura-Shima
Mao Nakamura-Shima
RSRie Shibuya-Takahashi
Rie Shibuya-Takahashi
RIRyo Ito
Ryo Ito
ASAkira Sugawara
Akira Sugawara
KTKeiichi Tamai
Keiichi Tamai

13 April 2014 in Oral Oncology
Verified
Journal Article
Closed access
TSTomohiro Sakashita
Tomohiro Sakashita
AHAkihiro Homma
Akihiro Homma
RHRyuichi Hayashi
Ryuichi Hayashi
KKKazuyoshi Kawabata
Kazuyoshi Kawabata
KYKunitoshi Yoshino
Kunitoshi Yoshino
MFMasato Fujii
Masato Fujii